Enanta Pharmaceuticals (ENTA) Non Operating Income (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Non Operating Income data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Non Operating Income fell 313.15% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.5 million (down 146.91% YoY) and the FY2025 annual result came in at $1.8 million, down 53.88% from the prior year.
• Non Operating Income retreated to -$1.2 million in Q1 2026, from -$661000.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $3.9 million in Q2 2023 to a low of -$1.2 million in Q1 2026.
• A 5-year average of $787117.6 and a median of $714000.0 in 2022 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income jumped 883.72% — and 2026, when it slumped 313.15%.
• Tracing ENTA's Non Operating Income over 5 years: stood at $993000.0 in 2022, then decreased by 13.7% to $857000.0 in 2023, then declined by 2.33% to $837000.0 in 2024, then plunged by 178.97% to -$661000.0 in 2025, then slumped by 86.38% to -$1.2 million in 2026.
• The last three Non Operating Income figures came in at -$1.2 million (Q1 2026), -$661000.0 (Q4 2025), and -$282000.0 (Q3 2025), per Business Quant data.